101. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
- Author
-
Hoff FW, Chung SS, Patel PA, Premnath N, Khatib J, Tadic-Ovcina M, AhmedRabie A, Helton D, Yohannes S, Shahan J, Patel H, Geethakumari PR, Vusirikala M, Collins RH, and Madanat YF
- Subjects
- Transplantation, Homologous, Graft vs Host Disease prevention & control, Recurrence, Electronic Health Records, Retrospective Studies, Transplantation Conditioning, Risk Assessment, Humans, Male, Female, Young Adult, Adult, Middle Aged, Aged, Survival Rate, Regression Analysis, Cyclophosphamide administration & dosage, Cyclophosphamide therapeutic use, Chimerism, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Myelodysplastic Syndromes pathology, Myelodysplastic Syndromes therapy
- Abstract
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for high-risk myeloid malignancies. Post-transplant cyclophosphamide (PT-Cy) has proven to be effective for graft versus host disease (GVHD) prophylaxis. Given that graft-versus-tumor (GVT) effect plays a major role in reducing the risk of disease relapse, the application of PT-Cy must balance the risk of relapse. Mixed chimerism (MC) refers to a state of concurrent presence of recipient and donor cells post allo-HSCT which may precede relapse disease., Objective: We investigated the impact of PT-Cy on early MC (EMC) and disease relapse in patients with a myeloid malignancy post allo-HSCT., Study Design: This retrospective single-center study included patients that underwent allo-HSCT between 2015 and 2021. Patient and disease characteristics were collected from the electronic health records. EMC was defined as <95% donor cells at day 90-120 post allo-HSCT., Results: A total of 144 patient that received an allo-HSCT were included in the study. One hundred and eight (75%) patients received PT-Cy as part of the GVHD prophylaxis regimen. The majority underwent allo-HSCT for acute myeloid leukemia (62%) or myelodysplastic syndrome (31%). Sixty-five percent received allo-HSCT from a matched unrelated donor transplant and 65% received a myeloablative conditioning regimen. A lower rate of chronic GVHD (p = 0.03) and a higher rate of EMC (p = 0.04) were observed in patients that received PT-Cy. PT-Cy was not associated with overall survival (OS) and relapse-free survival (RFS). Multivariable analysis identified measurable residual disease status (p = 0.003), hematopoietic cell transplantation-specific comorbidity index (p = 0.012) and chronic GVHD (p = 0.006) as independent prognostic variables for OS. AML-adverse risk (p = 0.004) and EMC (p = 0.018) were independently prognostic for RFS. While EMC overall was not significantly associated with higher risk of relapse, EMC was associated with shorter RFS within adverse-risk AML patients., Conclusion: Our study shows that PT-Cy was associated with an increased risk of EMC. The predictive value of EMC for relapse remains unclear and may depend on the underlying disease, which should be validated in a larger cohort., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF